• Represented Petitioner BicycleRD in IPR Reviews (IPR2020-01569 and IPR2020-01626) of USPNs 8,748,105 and 8,742,070, entitled “Method for Selecting a Candidate Drug Compound.” 
    • Represented Petitioner, Eli Lilly & Co., in PGR Review (PGR2019-00043) of USPN 10,011,654, entitled “Antibodies Directed to IL-17A/IL-17F Heterodimers.” 
    • Advised Royalty Pharma in several transactions, including those relating to Risdiplam, Seltorexant, Vertex’s cystic fibrosis treatments, IDHIFA® (enasidenib), Entyvio® (vedolizumab), Prevymis™ (letermovir), Tazverik® (tazemetostat), and Promacta® (eltrombopag).
    • Represented a clinical-stage biopharmaceutical company in two Inter Partes Reviews of patents relating to peptide technologies.
    • Represented a major pharmaceutical and biotechnology company in a district court litigation and copending Post-Grant Review (PGR) petition relating to a monoclonal antibody therapy.
    • Represented a major pharmaceutical company in securing a reissue patent in the U.S. Patent and Trademark Office related to its blockbuster cancer treatment.
    • Advised Cerberus and PaxVax on patent issues related to the sale of PaxVax to Emergent BioSolutions. 
    • Harvey Mudd College, B.S., 2001, High Honors, Dow Chemical Foundation Scholar
    • Columbia University, Ph.D., 2006
    • Georgetown University Law Center, J.D., 2013
    • New York
    • United States Patent and Trademark Office
    • United States Court of Appeals for the Federal Circuit
    • Licensing Executive Society
    • American Chemical Society